
Michael J. Schmitt
Examiner (ID: 16100, Phone: (571)270-7047 , Office: P/1629 )
| Most Active Art Unit | 1629 |
| Art Unit(s) | 1629 |
| Total Applications | 823 |
| Issued Applications | 449 |
| Pending Applications | 81 |
| Abandoned Applications | 317 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20671864
[patent_doc_number] => 12612364
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-04-28
[patent_title] => Salts and solid forms of 4-hydroxy-
[patent_app_type] => utility
[patent_app_number] => 19/408193
[patent_app_country] => US
[patent_app_date] => 2025-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 2
[patent_no_of_words] => 32008
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19408193
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/408193 | Salts and solid forms of 4-hydroxy- | Dec 2, 2025 | Issued |
Array
(
[id] => 20458251
[patent_doc_number] => 20260007671
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2026-01-08
[patent_title] => TREATMENT OF HCM WITH PYRIMIDINEDIONE COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 19/288391
[patent_app_country] => US
[patent_app_date] => 2025-08-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23418
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19288391
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/288391 | TREATMENT OF HCM WITH PYRIMIDINEDIONE COMPOUNDS | Jul 31, 2025 | Pending |
Array
(
[id] => 20335421
[patent_doc_number] => 20250339541
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-11-06
[patent_title] => ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS
[patent_app_type] => utility
[patent_app_number] => 19/192108
[patent_app_country] => US
[patent_app_date] => 2025-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 84686
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 351
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19192108
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/192108 | ASGPR-binding compounds for the degradation of extracellular proteins | Apr 27, 2025 | Issued |
Array
(
[id] => 20098847
[patent_doc_number] => 20250228783
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-17
[patent_title] => PHARMACEUTICAL FORMULATIONS OF A BRUTON'S TYROSINE KINASE INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 19/172172
[patent_app_country] => US
[patent_app_date] => 2025-04-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42632
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 160
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19172172
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/172172 | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor | Apr 6, 2025 | Issued |
Array
(
[id] => 20700281
[patent_doc_number] => 12622972
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-05-12
[patent_title] => ASGPR-binding compounds for the degradation of extracellular proteins
[patent_app_type] => utility
[patent_app_number] => 19/081876
[patent_app_country] => US
[patent_app_date] => 2025-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 138
[patent_figures_cnt] => 139
[patent_no_of_words] => 84942
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 370
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19081876
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/081876 | ASGPR-binding compounds for the degradation of extracellular proteins | Mar 16, 2025 | Issued |
Array
(
[id] => 20120411
[patent_doc_number] => 20250235442
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-24
[patent_title] => Piperidine Urea Derivatives for Use as Inotropic Agents
[patent_app_type] => utility
[patent_app_number] => 19/060522
[patent_app_country] => US
[patent_app_date] => 2025-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5874
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19060522
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/060522 | Piperidine urea derivatives for use as inotropic agents | Feb 20, 2025 | Issued |
Array
(
[id] => 20057327
[patent_doc_number] => 20250195549
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-19
[patent_title] => NEW USE
[patent_app_type] => utility
[patent_app_number] => 18/972566
[patent_app_country] => US
[patent_app_date] => 2024-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14949
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18972566
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/972566 | NEW USE | Dec 5, 2024 | Pending |
Array
(
[id] => 19554721
[patent_doc_number] => 20240366513
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => Methods For Administering Weight Loss Medications
[patent_app_type] => utility
[patent_app_number] => 18/770144
[patent_app_country] => US
[patent_app_date] => 2024-07-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12187
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18770144
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/770144 | Methods For Administering Weight Loss Medications | Jul 10, 2024 | Pending |
Array
(
[id] => 20031835
[patent_doc_number] => 20250170057
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-29
[patent_title] => METHODS OF TREATING EOSINOPHILIC ESOPHAGITIS
[patent_app_type] => utility
[patent_app_number] => 18/755113
[patent_app_country] => US
[patent_app_date] => 2024-06-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54072
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18755113
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/755113 | METHODS OF TREATING EOSINOPHILIC ESOPHAGITIS | Jun 25, 2024 | Pending |
Array
(
[id] => 19769847
[patent_doc_number] => 20250051273
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-13
[patent_title] => Glucose and Lipid Metabolism Regulating Agents, Pharmaceutical Compositions Comprising the Same, and Treatment Methods
[patent_app_type] => utility
[patent_app_number] => 18/755133
[patent_app_country] => US
[patent_app_date] => 2024-06-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6014
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 156
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18755133
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/755133 | Glucose and Lipid Metabolism Regulating Agents, Pharmaceutical Compositions Comprising the Same, and Treatment Methods | Jun 25, 2024 | Pending |
Array
(
[id] => 19631106
[patent_doc_number] => 20240409555
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-12
[patent_title] => CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/747129
[patent_app_country] => US
[patent_app_date] => 2024-06-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 70830
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18747129
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/747129 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | Jun 17, 2024 | Pending |
Array
(
[id] => 19682285
[patent_doc_number] => 20250000830
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-02
[patent_title] => DEUTERATED ANALOGS OF D-SERINE AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/731580
[patent_app_country] => US
[patent_app_date] => 2024-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16771
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18731580
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/731580 | DEUTERATED ANALOGS OF D-SERINE AND USES THEREOF | Jun 2, 2024 | Pending |
Array
(
[id] => 19915222
[patent_doc_number] => 12290568
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-06
[patent_title] => ASGPR-binding compounds for the degradation of extracellular proteins
[patent_app_type] => utility
[patent_app_number] => 18/653610
[patent_app_country] => US
[patent_app_date] => 2024-05-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 138
[patent_figures_cnt] => 162
[patent_no_of_words] => 85073
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 353
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18653610
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/653610 | ASGPR-binding compounds for the degradation of extracellular proteins | May 1, 2024 | Issued |
Array
(
[id] => 19447416
[patent_doc_number] => 20240307546
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-19
[patent_title] => ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS
[patent_app_type] => utility
[patent_app_number] => 18/653655
[patent_app_country] => US
[patent_app_date] => 2024-05-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 88162
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 391
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18653655
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/653655 | ASGPR-binding compounds for the degradation of extracellular proteins | May 1, 2024 | Issued |
Array
(
[id] => 19417225
[patent_doc_number] => 20240293348
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => Compositions And Methods For Prevention And Reduction Of Traumatic Brain Injury
[patent_app_type] => utility
[patent_app_number] => 18/646642
[patent_app_country] => US
[patent_app_date] => 2024-04-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6749
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 158
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18646642
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/646642 | Compositions And Methods For Prevention And Reduction Of Traumatic Brain Injury | Apr 24, 2024 | Pending |
Array
(
[id] => 19448846
[patent_doc_number] => 20240308976
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-19
[patent_title] => COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/640889
[patent_app_country] => US
[patent_app_date] => 2024-04-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 61320
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18640889
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/640889 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | Apr 18, 2024 | Pending |
Array
(
[id] => 19554836
[patent_doc_number] => 20240366628
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => USE OF ZINC PORPHYRIN AS AN ANTIMICROBIAL
[patent_app_type] => utility
[patent_app_number] => 18/638849
[patent_app_country] => US
[patent_app_date] => 2024-04-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19386
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18638849
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/638849 | USE OF ZINC PORPHYRIN AS AN ANTIMICROBIAL | Apr 17, 2024 | Pending |
Array
(
[id] => 19402080
[patent_doc_number] => 20240285591
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-29
[patent_title] => METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS)
[patent_app_type] => utility
[patent_app_number] => 18/628353
[patent_app_country] => US
[patent_app_date] => 2024-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20023
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18628353
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/628353 | METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS) | Apr 4, 2024 | Abandoned |
Array
(
[id] => 19343499
[patent_doc_number] => 20240252462
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION
[patent_app_type] => utility
[patent_app_number] => 18/627708
[patent_app_country] => US
[patent_app_date] => 2024-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21379
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18627708
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/627708 | Methods of providing solriamfetol therapy to subjects with impaired renal function | Apr 4, 2024 | Issued |
Array
(
[id] => 19510456
[patent_doc_number] => 20240342142
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-17
[patent_title] => METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS)
[patent_app_type] => utility
[patent_app_number] => 18/628366
[patent_app_country] => US
[patent_app_date] => 2024-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19133
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18628366
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/628366 | METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS) | Apr 4, 2024 | Abandoned |